Clin. lab. Haemat. 1983, **5**, 433–436

Author index to Volume 5

AINSWORTH M., see Colvin B.T. *et al.*
ANDREWS N.J. & BLOOR K. Autologous blood collection in abdominal vascular surgery. Assessment of a low pressure blood salvage system with particular reference to the preservation of cellular elements, triglyceride, complement and bacterial content in the collected blood 361
ARONSTAM A., WASSEF M., HAMAD Z., CARTLIDGE J. & MCLELLAN D. A double-blind controlled trial of two dose levels of factor VIII in the treatment of high risk haemarthroses in haemophilia A 157, see also McLellan D.S. *et al.*

BAIN B.J. Some influences on the ESR and the fibrinogen level in healthy subjects 45, see also England J.M. *et al.*
BALDWIN C. & ROATH S. The evaluation of neutropenia: the use of the granulocyte mobilization test 353
BARRETT A.J., see Kendra J.R. *et al.*
BATTEN E., see Eridani S. *et al.*
BELLINGHAM A.J., see Summerfield G.P. *et al.*
BIFFIN A., see Napier J.A.F. & Biffin A.
BIRD G.W.G., see Hamilton D.V. *et al.*
BLACK A.J., see Hamilton D.V. *et al.* and also Maidment C.G. *et al.*
BLOOM A.L., see Giddings J.C. *et al.*
BLOOR K., see Andrews N.J. & Bloor K.
BOWELL P.J. & SALATA M.K. A comparison of PVP and methyl cellulose as rouleaux inducing reagents in the automated anti-D quantification method 295
BOWES A., see Hegde U.M. *et al.*
BOWLEY N., see Mehta A.B. *et al.*
BRAZIER A.M., see Gardner B. *et al.*
BROOM G., see England J.M. *et al.*
BUCHANAN G.R., see Sasaki J. *et al.*
BUCKLEY C., see Colvin B.T. *et al.*
BUNCH C., see Summerfield G.P. *et al.*
BYROM N., see Kendra J.R. *et al.*

CARTER A.C., see Gunson H.H. *et al.*
CARTLIDGE J., see Aronstam A. *et al.*
CASTELLA A., see Davey F.R. *et al.*
CATOVSKY D., see Mehta A.B. *et al.*
CAVE R.J., HOLDER R.L., MORRIS T.K., TAYLOR J., SMITH D. & SHINTON N.K. An evaluation of the Technicon H6000 haematology system 203
CHAMBERS D., see Kendra J.R. *et al.*
CHETTY M.C., see England J.M. *et al.*
CHONG L.L., SUSSMAN I.I. & SPAET T.H. Monitoring heparin therapy–a role for chromogenic assay 61
COLVIN B.T., AINSWORTH M. & BUCKLEY C. Experience with highly purified porcine factor VII in a patient with maemophilia A and a factor VIII inhibitor 55
COTES P.M., see Hellmann A. *et al.*
COTTAM G.L., see Sasaki J. *et al.*
COUSINS S., see England J.M. *et al.*
CROSLAND-TAYLOR P.J., see England J.M. *et al.*
CZINK E., see Minh D-Q. *et al.*

DALY H.M. & SCOTT G.L. Acute monocytic leukaemia complicating polycythaemia rubra vera: successful response to chemotherapy with recurrence of polycythaemia 319
DARNBOROUGH J., see Hamilton D.V. *et al.*
DAVEY F.R., CASTELLA A., LAUENSTEIN K., HUBBELL C. & OATES R.P. Prognostic significance of the revised French-American-British classification for acute lymphocytic leukaemia 343
DAVSON J. & GEARY C.G. Lymphopenia in histiocytic medullary reticulosis 67
DAWSON D.W., see Fish D.I. & Dawson D.W.
DEAN A., see England J.M. *et al.*
DEVEREUX S., see Hegde U.M. *et al.*

EASTON A.C., see Thomson J.M. *et al.*
EL-MOHANDES E.A-M. & HAYHOE F.G.J. 5′-nucleotidase activity in myeloma cells 265

ENGLAND J.M., BAIN B.J., CHETTY M.C., BROOM G. & DEAN A. An assessment of the Coulter Counter Model S Plus II and III 399

ENGLAND J.M., CHETTY M.C., GARVEY B., LEWIS S.M., WARDLE J., COUSINS S., CROSLAND-TAYLOR P.J. & SYNDERCOMBE-COURT D. Testing of calibration and quality control material used with automatic blood counting apparatus: application of the Protocol devised by the British Committee for Standardization in Haematology 83

ERIDANI S., PEARSON T.C., SAWYER B., BATTEN E. & WETHERLEY-MEIN G. Erythroid colony formation in primary proliferative polycythaemia, idiopathic erythrocytosis and secondary polycythaemia: sensitivity to erythropoietic stimulating factors 121

EVANS D.I.K., see Sankarankutty M. & Evans D.I.K.

EVATT B.L., see Rose M. *et al.*

FARAGHER E.B., see Thomson J.M. *et al.*

FISH D.I. & DAWSON D.W. Comparison of methods used in commercial kits for the assay of serum vitamin B_{12} 271

FISHER D., see Hegde U.M. *et al.*

FLETCHER S., see Gunson H.H. *et al.*

FOROOZANFAR N., see Kendra J.R. *et al.*

FRASER C. & ROWAN R.M. Three-year evaluation of a commercial quality control reagent for cell counting and sizing 93

FÜST G., see Minh D-Q. *et al.*

GALE R., see Levene C. *et al.*

GALLOWAY M.J., MACKIE M.J. & MCVERRY B.A. Circulating plasmin-antiplasmin complexes in acute leukaemia 243

GAMINARA E.J., see Slater N.G.P. & Gaminara E.J.

GARDNER B., GHOSH S., BRAZIER D.M. & HOLBURN A.M. Quantitative quality control of antiglobulin reagents 215

GARVEY B., see England J.M. *et al.*

GEARY C.G., see Davson J. & Geary C.F.

GHOSH S., see Gardner B. *et al.*

GIDDINGS J.C., BLOOM A.L., KELLY M.A. & SPRATT H.C. Human factor IX inhibitors: immunochemical characteristics and treatment with activated concentrate 165

GLOSTER E.S., see Strauss R.A. *et al.*

GRAHAM H. & WHITELAW A. The enhancement of *Dolichos biflorus* and certain other lectins using increased concentrations of sodium chloride 231

GREAVES M.F., see Maidment C.G. *et al.*

GRUNBERG L., see Levene C. *et al.*

GUNSON H.H., MAKAR Y.F. & FLETCHER S. Five-day storage of platelet concentrates. I. *In-vitro* studies 75

GUNSON H.H., MERRY A.H., MAKAR Y., THOMSON E.E. & CARTER A.C. Five-day storage of platelet concentrates. II. *In-vivo* studies 287

HAFF E., see Rose M. *et al.*

HAMAD Z., see Aronstam A. *et al.*

HAMILTON D.V., BLACK A.J., DARNBOROUGH J. & BIRD G.W.G. Haemolytic-uraemic syndrome and T-activation of red blood cells 109

HARMOINEN A., UPPA H., LEHTINEN M., JOKELA H. & KOIVULA T. Fibrinogen: a comparison of an immunoturbidimetric method with four conventional methods 101

HARRISON J.F., see McGregor M. *et al.*

HAYHOE F.G.J., see El-Mohands E.A-M. & Hayhoe F.G.J.

HEDGE U.M., WILLIAMS K., DEVEREUX S., BOWES A., POWELL D. & FISHER D. Platelet associated IgG and immune thrombocytopenia in lymphoproliferative and autoimmune disorders 9

HELLMANN A., ROTOLI B., COTES P.M. & LUZZATTO L. Familial erythrocytosis with over-production of erythropoietin 335

HEMMINGWAY A., see Mehta A.B. *et al.*

HENRY K., see Kendra J.R. *et al.*

HOBBS J.R., see Kendra J.R. *et al.*

HOLBURN A.M., see Gardner A.M. *et al.*

HOLDER R.L., see Cave R.J. *et al.*

HOLLÁN S.R., see Minh D-Q. *et al.*

HORSLER H., see Kendra J.R. *et al.*

HUBBELL C., see Davey F.R. *et al.*

HUGH-JONES K., see Kendra J.R. *et al.*

JAMES D.C.O., see Kendra J.R. *et al.*

JOKELA H., see Harmoinen A. *et al.*

JOSS D.V., see Kendra J.R. *et al.*

KELLY M.A., see Giddings J.C. *et al.*
KENDRA J.R., LUCAS C.F., CHAMBERS D., WILLIAMSON S., BYROM N., FOROOZANFAR N., JOSS D.V., HORSLER H., JAMES D.C.O., SELWYN S., ROGERS T.R., HENRY K., PHILLIPS R.H., BARRETT A.J., HUGH-JONES K. & HOBBS J.R. Bone marrow transplantation for severe aplastic anaemia a review of the Westminster experience of 24 cases 131
KERNOFF L.M. & MALAN E. Complement (C3) binding to platelets in autoimmune thrombocytopenia 1
KIRKHAM R., see McGregor M. *et al.*
KITTINGER S.P., see Strauss R.A. *et al.*
KOIVULA T., see Harmoinen A. *et al.*

LAUENSTEIN K., see Davey F.R. *et al.*
LEHTINEN M., see Harmoinen A. *et al.*
LEVENE C., SELA R., GRUNBERG L., GALE R., LOMAS C. & TIPPETT P. The Rh antigen Tar (Rh 40) causing haemolytic disease of the newborn 303
LEWIS S.M., see England J.M. *et al.*
LOMAS C., see Levene C. *et al.*
LOTT M., see Mehta A.B. *et al.*
LUCAS C.F., see Kendra J.R. *et al.*
LUZZATTO L., see Hellman A. *et al.*

MACKIE M.J., see Galloway M.J. *et al.*
MAIDMENT C.G., Greaves M.F. & BLACK A.J. T-cell leukaemia presenting with hyperuricaemia, acute renal failure and gout 423
MAKAR Y., see Gunson H.H. *et al.*
MALAN E., see Kernoff L.M. & Malan E.
MALKOVSKA V., see Mitchell E.B. *et al.*
MCCANN S.R., see Smith O. *et al.*
MCGREGOR M., HARRISON J.F. & KIRKHAM R. A study of the routine use of the Imugard IG500 Leukocyte Removal Filter illustrating a possible cause of transfusion reactions and a method of prevention 279
MCLELLAN D.S., PELLY C., MCLELLAN H.G. & ARONSTAM A. The stability of VIII: C in frozen stored plasma samples–re-examined 197, see also Aronstam A. *et al.*
MCLELLAN H.G., see McLellan D.S. *et al.*
MCVERRY B.A., see Galloway M.J. *et al.*
MEHTA A.B., CATOVSKY D., O'BRIEN C.J., LOTT M., BOWLEY N. & HEMMINGWAY A. Massive retroperitoneal lymphadenopathy as a terminal event in hairy cell leukaemia 259
MERRY A.H., THOMSON E.E., RAWLINSON V.I. & STRATTON F. The quantification of C3 fragments on erythrocytes: estimation of C3 fragments on normal cells, acquired haemolytic anaemia cases and correlation with agglutination of sensitized cells 387, see Gunson H.H. *et al.*, and Stratton F. *et al.*
MINH D-Q., CZINK E., MÓD A., FÜST G. & HOLLÁN S.R. Serial complement measurements in a patient with leukaemia 23
MITCHELL E.B., PLATTS-MILLS T.A.E., PEREIRA R.S., MALKOVSKA V. & WEBSTER A.D. Acquired basophil and eosinophil deficiency in a patient with hypogammaglobulinaemia associated with thymoma 253
MÓD A., see Minh D-Q. *et al.*
MORGAN B.B., see Strauss R.A. *et al.*
MORRIS T.K., see Cave R.J. *et al.*

NAPIER J.A.F. & BIFFIN A. The importance of cross-match/transfusion ratio and intervals between successive cross-matches in determining red cell outdate rates 379

OATES R.P., see Davey F.R. *et al.*
O'BRIEN C.J., see Mehta A.B. *et al.*

PEARSON T.C., see Eridani S. *et al.*
PELLY C., see McLellan D.S. *et al.*
PEREIRA R.S., see Mitchell E.B. *et al.*
PHILLIPS R.H., see Kendra J.R. *et al.*
PLATTS-MILLS T.A.E., see Mitchell E.B. *et al.*
POWELL D., see Hegde U.M. *et al.*

RAWLINSON V.I., see Merry A.H. *et al.*, see also Stratton F. *et al.*
ROATH S., see Baldwin C. & Roath S.
ROGERS T.R., see Kendra J.R. *et al.*
ROSE M., WIDEMAN C.S., EVATT B.L. & HAFF E. A comparison of antithrombin III procedures 185
ROTOLI B., see Hellmann A. *et al.*
ROWAN R.M., see Fraser C. & Rowan R.M.

SALATA M.K., see Bowell P.J. & Salata M.K.
SANKARANKUTTY M. & EVANS D.I.K. Chronic arthropathy in von Willebrand's disease 149
SASAKI J., WATERMAN M.R., BUCHANAN G.R. & COTTAM G.L. Plasma and erythrocyte lipids in sickle cell anaemia 35
SAWYER B., see Eridani S. *et al.*
SCHANFIELD M.S., see Strauss R.A. *et al.*
SCOTT G.L., see Daly H.M. & Scott G.L.
SELA R., see Levene C. *et al.*
SELWYN S., see Kendra J.R. *et al.*
SHINTON N.K., see Cave R.J. *et al.*
SLATER N.G.P. & GAMINARA E.J. A single vein technique for use with a continuous flow cell separator 145
SMITH D., see Cave R.J. *et al.*
SMITH D.S., see Young D.J. & Smith D.S.
SMITH O., TEMPERLEY I.J., TIPTON K. & MCCANN S.R. A pyruvate kinase variant with an increased affinity for phospho-enolpyruvate in an individual with congenital non-spherocytic haemolytic anaemia 237
SPAET T.H., see Chong L.L. *et al.*
SPRATT H.C., see Giddings J.C. *et al.*
STRATTON F., RAWLINSON V.I., MERRY A.H. & THOMSON E.E. Positive direct anti-globulin test in normal individuals. II. 17, see also Merry A.H. *et al.*
STRAUSS R.A., GLOSTER E.S., SCHANFIELD M.S., KITTINGER S.P. & MORGAN B.B. Anaphylactic transfusion reaction associated with a possible anti-A2m(1) 371
SUMMERFIELD G.P., BELLINGHAM A.J., BUNCH C. & WOODROW J.C. Successful treatment of chronic cutaneous graft-versus-host-disease (GVHD) with penicillamine 313
SUSSMAN I.I., see Chong L.L. *et al.*
SYNDERCOMBE-COURT D., see England J.M. *et al.*

TAYLOR J., see Cave R.J. *et al.*
TEMPERLEY I.J., see Smith O. *et al.*
THOMSON E.E., see Gunson H.H. *et al.*, and also Merry A.H. *et al.*
THOMSON J.M., EASTON A.C. & FARAGHER E.B. The use of Vacutainer tubes for collection and storage of blood for coagulation testing 413, see also Stratton F. *et al.*
TIPPETT P., see Levene C. *et al.*
TIPTON K., see Smith O. *et al.*

UPPA H., see Harmoinen A. *et al.*

WARDLE J., see England J.M. *et al.*
WASSEF M., see Aronstam A. *et al.*
WATERMAN M.R., see Sasaki J. *et al.*
WEBSTER A.D., see Mitchell E.B. *et al.*
WETHERLEY-MEIN G., see Eridani S. *et al.*
WHITELAW A., see Graham H. & Whitelaw A.
WIDEMAN C.S., see Rose M. *et al.*
WILLIAMS K., see Hegde U.M. *et al.*
WILLIAMSON S., see Kendra J.R. *et al.*
WOODROW J.C., see Summerfield G.P. *et al.*

YOUNG D.J. & SMITH D.S. A further example of the low frequency antigen Pt^a 307

Clin. lab. Haemat. 1983, **5**, 437–439

Subject index to Volume 5

Acquired haemolytic anaemia 387
Activated concentrate 165
Anaemia
  acquired haemolytic 387
  aplastic 131
  non-spherocytic haemolytic 237
  sickle cell 35
Anaphylactic transfusion reaction 371
Anti-A2m(1) 371
Anticoagulant clinics, therapeutic quality control 325*c**
Anti-D potency 295
Antigen Pt^a, low frequency 307
Antiglobulin
  reagents 215
  test 17, 387
Antithrombin III, comparison of procedures 185
Aplastic anaemia 131
Arthropathy 149
Autoimmune
  disorders 9
  thrombocytopenia 1
Autologous blood transfusion 361
Automatic blood counting apparatus 83

Bacterial contamination 361
Basophil deficiency 253
Blood bank management 379
Blood coagulation testing 413
Blood donors 17
Bone marrow
  failure 353
  transplantation 131
Book reviews 116, 235, 331, 429
Bowel disease 427*c*
British Committee for Standardization in Haematology: application of Protocol 83

C3 fragments, quantification on erythrocytes 387
Cell counting and sizing 93
Chromogenic assay 61
Chromosome anomaly, 15/17 translocation 324*c*
Chronic inflammatory bowel disease 427*c*
Coagulometers, multicentre comparison 177
Commercial quality control reagent, evaluation of 93
Complement (C3) 1
Continuous flow cell separator 145
Coulter Counter, assessment of models 399
Coulter Counter Model S Plus 93
Cross-match/transfusion ratios 379
Cyclosporin A 131

Dolichos biflorus 231

Eosinophil deficiency 253
Erythrocyte lipids 35
Erythrocyte sedimentation rate 45
Erythrocytes, quantification of fragments on 387
Erythrocytosis
  familial 335
  idiopathic 121
Erythroid colony formation 121
Erythropoietic factors 121
Erythropoietin 335

FAB classification 343
Factor VIII
  highly purified porcine 55
  inhibitor 55
  reduced levels 427*c*
  stabiiity 197
  two-dose levels 157
Factor IX inhibitors
  immunochemical characteristics 165
  treatment with active concentrate 165
Felty's syndrome 328*c*
Fibrinogen
  comparison of methods 101
  degradation products 101
  level in healthy subjects 45
Fitzgerald factor deficiency 113*c*
Five'-nucleotidase activity 265

*c denotes reference to correspondence

Gout and T-cell leukaemia 423
Graft-versus-host-disease 313
Granulocyte
  colony formation 328*c*
  mobilization test 353

Haemarthroses 157
Haemoglobin Lepore Boston 323*c*
Haemolysis 237
Haemolytic
  acquired anaemia 387
  disease 303
  uraemic syndrome 109
Haemophilia A
  haemarthroses 157
  with inhibitors 55
Heparin therapy 61
Hepatitis B surveillance 327*c*
Histiocytic medullary reticulosis 67
Hodgkin's disease 324*c*
Hyperuricaemia with T-cell leukaemia 423
Hypogammaglobulinaemia associated with thymoma 253

IgA deficiency 371
IgG, platelet associated 9
Immune complexes 23
Immunoglobulin G immunohaematology 17
Imugard IG5000 Leukocyte Removal Filter 279
Isotopic assay 328*c*

Lectins, enhancement of 231
Leukaemia
  granulocytic 113*c*
  hairy cell 259
  lymphocytic 343
  monocytic 319
  plasmin-antiplasmin complexes in 243
  promyelocytic 324*c*
  serial complement measurements 23
  T-cell 423
Lipids, plasma and erythrocyte 35
Lymphadenopathy 259
Lymphopenia 67
Lymphoproliferative disorders 9

Manual tilt-tube methods, multicentre comparison 177
Methyl cellulose as a rouleaux inducing agent 295
Myeloid precursors 328*c*
Myeloma cells, 5'-nucleotidase activity in 265

Neutropenia, evaluation of 353

Outdate rates, red cell 379

Penicillamine 313
Phosphoenolpyruvate 237
Plasma
  complement 361
  lipids 35
  protein reaction 279
  stored 197
  triglyceride 361
Plasmin-antiplasmin complexes 243
Platelet
  binding to complement 1
  concentrates 75, 287
  storage 75, 287
Polycythaemia 323*c*
  primary proliferative 121
  rubra vera 319
  secondary 121
Porcine factor VIII, 55
Post-tranfusion purpura 324*c*
Prothrombin time performance 177
Purpura, post-transfusion 324*c*
PVP as a rouleaux inducing reagent 295

Red cell outdate rates 379
Renal failure and T-cell leukaemia 423
Reticulosis, histiocytic medullary 67
Rh antigen Tar 303
Rouleaux inducers 295

Separator, continuous flow cell 145
Sickle cell anaemia 35
Single vein technique 145
Sodium chloride, using increased concentrations to enhance lectins 231
Steroid-responsive post-transfusion purpura 324*c*

T-activation of red blood cells 109
T-cell leukaemia 423
Technicon H6000, evaluation of 203
Therapeutic quality control 325*c*
Thrombocytopenia
  autoimmune 1
  immune 9
Thymoma, with hypogammaglobulinaemia 253

Transfusion
autologous 361
reactions 279, 371
Triglyceride plasma 361
Vacutainer tubes, use for collection and storage 413
Vitamin B_{12} comparison of methods used in commercial kits for assay of 271
von Willebrand's disease 149